Fourth Quarter 2021 sales of $2.1 billion, up 11% or 13% constant currency
Full Year 2021 sales of $8.2 billion, up 22% or 20% constant currency
Above-market growth in both Surgical and Vision Care; sales momentum from key products, new product launches and commercial execution
Full Year 2021 cash from operations of $1.3 billion, free cash flow of $645 million
2022 guidance reflects continued sales and earnings growth
2022 outlook
The Company provided its full year 2022 outlook as follows. This outlook assumes that markets grow over 2021 in line with historical averages; that the impact from inflation moderates in the second half of the year; and that exchange rates as of mid-January 2022 prevail through year-end.
2022 outlook | Change vs. 2021 | ||
Net sales | $8.7 to $8.9 billion | +7% to +9% | |
Core operating margin(1) | 18% to 19% | ||
Interest expense and Other financial income & expense | $180 to $190 million | ||
Core effective tax rate(5) | 17% to 19% | ||
Core diluted EPS(1) | $2.35 to $2.45 | +13% to +18% |
Webcast and Conference Call Instructions
The Company will host a conference call on February 16 at 2:00 p.m. Central European Time / 8:00 a.m. Eastern Time to discuss its fourth quarter and full year 2021 earnings results. The webcast can be accessed online through Alcon's Investor Relations website, investor.alcon.com. Listeners should log on approximately 10 minutes in advance. A replay will be available online within 24 hours after the event.
https://finance.yahoo.com/news/alcon-reports-fourth-quarter-full-213000718.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.